514 related articles for article (PubMed ID: 18951988)
1. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
2. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
3. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
4. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Saftig P; Reiss K
Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
[TBL] [Abstract][Full Text] [Related]
5. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
[TBL] [Abstract][Full Text] [Related]
6. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
7. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
8. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries.
Tucher J; Linke D; Koudelka T; Cassidy L; Tredup C; Wichert R; Pietrzik C; Becker-Pauly C; Tholey A
J Proteome Res; 2014 Apr; 13(4):2205-14. PubMed ID: 24635658
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
Moss ML; Rasmussen FH
Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
[TBL] [Abstract][Full Text] [Related]
10. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
11. Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space.
Pruessmeyer J; Hess FM; Alert H; Groth E; Pasqualon T; Schwarz N; Nyamoya S; Kollert J; van der Vorst E; Donners M; Martin C; Uhlig S; Saftig P; Dreymueller D; Ludwig A
Blood; 2014 Jun; 123(26):4077-88. PubMed ID: 24833351
[TBL] [Abstract][Full Text] [Related]
12. Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.
Folkesson M; Li C; Frebelius S; Swedenborg J; Wågsäter D; Williams KJ; Eriksson P; Roy J; Liu ML
Thromb Haemost; 2015 Nov; 114(6):1165-74. PubMed ID: 26422658
[TBL] [Abstract][Full Text] [Related]
13. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
14. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Ebsen H; Schröder A; Kabelitz D; Janssen O
PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
[TBL] [Abstract][Full Text] [Related]
15. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth.
Maretzky T; Schulte M; Ludwig A; Rose-John S; Blobel C; Hartmann D; Altevogt P; Saftig P; Reiss K
Mol Cell Biol; 2005 Oct; 25(20):9040-53. PubMed ID: 16199880
[TBL] [Abstract][Full Text] [Related]
16. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
17. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
18. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
[TBL] [Abstract][Full Text] [Related]
19. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
20. The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.
Speck N; Brandsch C; Schmidt N; Yazdekhasti N; Hirche F; Lucius R; Rimbach G; Stangl GI; Reiss K
J Nutr; 2015 Jun; 145(6):1218-26. PubMed ID: 25926412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
